Helvetia Holding Ag Stock Earnings Reports

Straumann delivered a strong FY2025: revenue reached CHF 2.6bn (organic growth 8.9%), core gross margin 70.1% and core EBIT margin 25.2% (26.5% at constant 2024 FX). The company generated CHF 290m free cash flow despite one of its largest investment years (CHF 223m CapEx) and proposes a CHF 1.00/share dividend (+5%). Key growth drivers were record product launches (notably iEXCEL with >1m implants sold), strong adoption of the SIRIOS X3 scanner and rapid uptake of the Straumann AXS cloud platform (15,000+ users). Regionally, EMEA and Latin America were particularly strong (EMEA >11% organic growth; LATAM ~18%), North America accelerated through the year (Q4 organic 6.8%) and Asia Pacific showed solid underlying growth outside China; China was softer in H2 due to distributor destocking and the upcoming VBP process but management expects fundamentals to remain intact and a stronger second half in 2026. Transformation initiatives include transitioning ClearCorrect manufacturing to Smartee (expected to lower COGS and improve margins, with benefits phased through 2026), ramping Shanghai local production (improving supply resilience and cost), and chairside prosthetics/3D printing integration via the SprintRay partnership. Risks and headwinds called out: FX volatility (translation hit ~CHF100m revenue in 2025), U.S. tariffs (c. CHF 20m P&L hit in 2025) and China VBP timing/short-term destocking. Outlook for 2026: management expects high single-digit organic revenue growth and a core EBIT margin improvement of 30–60 basis points at constant 2025 exchange rates, with a second-half weighting anticipated (China/VBP and Smartee ramp timing).